Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-Users and Key Geographical Regions

The global cell and gene therapy CRO market is estimated to grow from USD 1.7 billion in the current year to USD 3.5 billion by 2035, at a CAGR of 7.1% during the forecast period, till 2035.

CELL AND GENE THERAPY CRO MARKET: GROWTH AND TRENDS

The recent FDA approval of several cell and gene therapies along with continuous advancements in this field demonstrates their wide potential in the treatment of various rare and complex diseases. Consequently, this promising treatment approach has attracted the attention of both investors and pharmaceutical developers. Notably, more than 90 cell and gene therapies have received global approval. Recent therapies that received approval include Elvediys (for duchenne muscular dystrophy) developed by Sarepta Therapeutics, Fucaso (for multiple myeloma) developed by IASO Bio, and Vyjuvek (for dystrophic epidermolysis bullosa) developed by Krystal Biotech. In addition, over 3,500 clinical trials are presently being conducted to explore cell and gene therapies across 16 therapeutic areas. This demonstrates the significant development initiatives being undertaken by stakeholders in this field. With the rapid evolution of cell and gene therapy, CROs provide essential expertise in refining study designs, navigating stringent regulatory environments, and ensuring a smooth shift from preclinical stages to clinical success. Currently, more than 105 industry stakeholders provide contract research services at various scales of operation. We are led to believe that the abovementioned factors will present lucrative market growth opportunities for contract service providers during the forecast period.

CELL AND GENE THERAPY CRO MARKET: KEY INSIGHTS

The report delves into the current state of the cell and gene therapy CRO market and identifies potential growth opportunities within the industry. Some key findings from the report include:

Presently, over 105 players (established as well as start-ups) claim to have the necessary capabilities to offer contract research services; majority of these firms are based in North America.
Stakeholders offer contract research services for cell and gene therapies across different scales of operations; close to 20% of the players offer all types of clinical services.

More than 65 deals have been inked between various stakeholders involved in this domain; acquisitions emerged as the most common type of partnership model.
The rising interest of players is reflected by the number of mergers and acquisitions reported in the last few years; 58% of such initiatives were signed to incorporate additional capabilities into their existing portfolio offerings.
Since 2019, more than 3,000 clinical trials have been registered for cell therapies; over 70% of the trials recently initiated are currently recruiting patients.
Close to 500 clinical trials (with over 48,000 enrolled patients) have been registered to investigate gene therapies, across different geographies.

In order to meet the rising demand for cell and gene therapies, stakeholders are striving to upgrade / expand their capabilities to enhance their respective service portfolios.
Total cost of ownership model offers an informed estimate of capital and operational expenses associated with the establishment and maintenance of a contract research facility, over a span of 20 years.
Driven by the increasing number of chronic indications (requiring novel personalized therapies), and ongoing research on cell and gene therapies, this market is anticipated to grow at a CAGR of 7.1%, till 2035.
About 25% of the market is expected to be captured by revenues generated from cell and gene therapies for oncological disorders; it is also worth highlighting that the CRO market in China is likely to grow at a faster pace.

CELL AND GENE THERAPY CRO MARKET: KEY SEGMENTS

Currently, the CAR-T Cell Therapy Market Segment Occupies the Largest Share of the Cell and Gene Therapy CRO Market

Based on the type of cell therapy, the market is segmented into CAR-NK, CAR-T, TCR-T, and others. It is worth highlighting that the CAR-T cell therapies segment is likely to dominate the market in the coming decade. This can be attributed to the proven efficacy of CAR-T cell therapies in treating CD19-positive hematological malignancies, acute lymphoblastic leukemia and multiple myeloma.

Ex Vivo Segment Holds the Maximum Share within the Cell and Gene Therapy CRO Market

Based on the type of genetic modification, the market is segmented into ex vivo and in vivo. It is worth highlighting that majority of the current cell and gene therapy CRO market is captured by the ex vivo segment and this trend is likely to remain the same in the forthcoming years. This can be attributed to the fact that ex vivo techniques utilize viral vectors, which are effective in delivering and integrating modified genetic material into cells.

Currently, the Clinical Segment Occupies the Largest Share of the Cell and Gene Therapy CRO Market

Based on the stage of development, the market is segmented into discovery, preclinical and clinical. It is worth highlighting that majority of the current cell and gene therapy CRO market is captured by the clinical segment and this trend is likely to remain the same in the forthcoming years. This can be primarily attributed to the rigorous clinical testing that these therapies undergo in order to meet the regulatory standards before commercialization.

Oncological Disorders Segment is Likely to Dominate the Cell and Gene Therapy CRO Market During the Forecast Period

Based on therapeutic areas, the market is segmented into blood disorders, cardiovascular disorders, dermatological disorders, immunological disorders, infectious diseases, metabolic disorders, musculoskeletal disorders, neurological disorders, oncological disorders, rare diseases, and other disorders. It is worth highlighting that majority of the current cell and gene therapy CRO market is captured by the oncological disorders segment and this trend is likely to remain the same in the forthcoming years.

Industry Players are Likely to Dominate the Cell and Gene Therapy CRO Market During the Forecast Period

Based on end users, the market is segmented into industry and non-industry players. It is worth highlighting that majority of the current cell and gene therapy CRO market is captured by industry players and this trend is likely to remain the same in the forthcoming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Majority share is expected to be captured by CROs based in North America. It is worth highlighting that, over the years, the market for Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Cell and Gene Therapy CRO Market

Altasciences
Allucent
CMIC
Labcorp
Linical
Medpace
PPD
Precision for Medicine
QPS
Syneos Health
CMED
ICON
Pharmalex
Novotech

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Business Development Executive, Company A
Clinical Trial Manager, Company B
Former Director, Marketing and Sales, Company C

CELL AND GENE THERAPY CRO MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cell and gene therapy CRO market, focusing on key market segments, including [A] type of cell therapy, [B] type of genetic modification, [C] stage of development, [D] therapeutic area, [E] end users and [F] key geographical regions.
Market Landscape: A comprehensive evaluation of contract research service providers engaged in cell and gene therapy CRO market, considering various parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] area of expertise, [E] scale of operation, [F] type of preclinical services offered, [G] type of clinical services offered, [H] type of regulatory services offered and [I] type of general support services offered.
Company Profiles: In-depth profiles of key cell and gene therapy contract research service providers based in North America, Europe and Asia-Pacific, focusing on [A] company overviews, [B] service portfolio, [C] insightful recent developments and [D] an informed future outlook.
Benchmark Analysis: A detailed benchmark analysis of the various players involved in this domain. It highlights the capabilities of the companies (in terms of their expertise across various services related to the development of cell and gene therapies).
Total Cost of Ownership: A thorough examination of the total cost of ownership for large and very large contract research organizations (CROs) specializing in cell and gene therapy, highlighting the costs associated in both the establishment and ongoing maintenance of a CRO facility over the short and long term.
Partnerships and Collaborations: An analysis of partnerships established in this domain, since 2015, based on several parameters, [A] year of partnership, [B] type of partnership, [C] area of expertise, [D] most active players and [E] regional distribution of partnership activity.
Merger and Acquisitions: A comprehensive analysis of the various mergers and acquisitions, focusing on multiple relevant parameters, including [A] year of agreement, [B] type of agreement, [C] key value drivers of the deal, [D] most active players (in terms of number of agreements signed) and [E] geographical location of companies.
Key Acquisition Targets: A detailed analysis of acquisitions that have taken place in the cell and gene therapy domain, taking into consideration the historical trend of the activity of players that have acquired other firms, and offering a means for other industry stakeholders to identify potential acquisition targets.
Clinical Trial Analysis: A detailed analysis of various cell and gene therapies, based on several parameters, such as [A] trial registration year, [B] trial status, [C] trial phase, [D ]enrolled patient population, [E] type of sponsor, [F] most active industry players (in terms of number of registered trials), [G] study design, [H] therapeutic area and [I] key geographical regions.
Business Model Analysis: A detailed discussion of the business models that are commonly adopted by the biopharmaceutical industry for outsourcing cell and gene therapies. In addition, it includes information on various factors that drive sponsors towards outsourcing and key parameters that sponsors must consider while choosing CROs at each phase of drug development process.
SWOT Analysis: A SWOT analysis of cell and gene therapy CRO services focuses on identifying industry-specific trends, key market drivers and challenges faced by companies providing these services.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading CROs in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What factors are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with the Research Team
Free Update if the Report is 6+ Months Old

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rates
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Contract Research Organizations (CROs)
5.3. Classification of CROs
5.4. Evolution of CROs
5.5. Modern CROs and Prevalent Outsourcing Trends
5.6. Type of Services Offered by CROs
5.7. Role of CROs in Development of Advanced Therapy Medicinal Products (ATMPs)
5.8. Advantages of Outsourcing Operations to CROs
5.9. Risks Associated with Outsourcing to CROs
5.10. Future Perspectives

6. GUIDE TO OUTSOURCING

6.1. Chapter Overview
6.2. Cell and Gene Therapy Research: Need for Outsourcing
6.3. Outsourcing Models
6.3.1. Transactional Outsourcing Model
6.3.2. Performance-based Business Model
6.3.3. Outcome-based Business Model
6.3.4. Staff Augmentation Model
6.3.5. Phase-Dependent Outsourcing Model
6.4. Selecting an Appropriate Outsourcing Model
6.5. Selecting a CRO Partner
6.6. Role of CROs in Drug Development
6.6.1. Discovery and Preclinical Research
6.6.2. Early Clinical Research
6.6.3. Clinical Research and Laboratory Services
6.6.4. Key Considerations for Outsourcing Cell and Gene Therapy Operations
6.7. Concluding Remarks

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Cell and Gene Therapy CROs: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Area of Expertise
7.2.5. Analysis by Type of Cell Therapy
7.2.6. Analysis by Scale of Operation
7.2.7. Analysis by Type of Preclinical Services Offered
7.2.8. Analysis by Type of Clinical Services Offered
7.2.9. Analysis by Type of Regulatory Services Offered
7.2.10. Analysis by Type of General Support Services Offered

8. COMPANY PROFILES

8.1. Chapter Overview
8.2. Aixial
8.2.1. Company Overview
8.2.2. Service Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Altasciences
8.3.1. Company Overview
8.3.2. Service Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. CMIC
8.4.1. Company Overview
8.4.2. Financial Information
8.4.3. Service Portfolio
8.4.4. Recent Developments and Future Outlook
8.5. ICON
8.5.1. Company Overview
8.5.2. Service Portfolio
8.5.3. Recent Developments and Future Outlook
8.6. Labcorp
8.6.1. Company Overview
8.6.2. Financial Information
8.6.3. Service Portfolio
8.6.4. Recent Developments and Future Outlook
8.7. Linical
8.7.1. Company Overview
8.7.2. Financial Information
8.7.3. Service Portfolio
8.7.4. Recent Developments and Future Outlook
8.8. Medpace
8.8.1. Company Overview
8.8.2. Financial Information
8.8.3. Service Portfolio
8.8.4. Recent Developments and Future Outlook
8.9. Novotech
8.9.1. Company Overview
8.9.2. Service Portfolio
8.9.3. Recent Developments and Future Outlook
8.10. PPD
8.10.1. Company Overview
8.10.2. Service Portfolio
8.10.3. Recent Developments and Future Outlook
8.11. Precision for Medicine
8.11.1. Company Overview
8.11.2. Service Portfolio
8.11.3. Recent Developments and Future Outlook
8.12. QPS
8.12.1. Company Overview
8.12.2. Service Portfolio
8.12.3. Recent Developments and Future Outlook
8.13. Syneos Health
8.13.1. Company Overview
8.13.2. Financial Information
8.13.3. Service Portfolio
8.13.4. Recent Developments and Future Outlook

9. BENCHMARKING ANALYSIS

9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. Cell and Gene Therapy CROs: Benchmark Analysis
9.3.1. Benchmarking Analysis of Small Players based in North America (Peer Group I)
9.3.2. Benchmarking Analysis of Mid-sized Players based in North America (Peer Group II)
9.3.3. Benchmarking Analysis of Large and Very Large Players based in North America (Peer Group III)
9.3.4. Benchmarking Analysis of Small Players based in Europe (Peer Group IV)
9.3.5. Benchmarking Analysis of Mid-sized Players based in Europe (Peer Group V)
9.3.6. Benchmarking Analysis of Large and Very Large Players based in Europe (Peer Group VI)
9.3.7. Benchmarking Analysis of Small, Mid-sized, Large and Very Large Players based in Asia-Pacific (Peer Group VII)
9.3.8. Benchmarking Analysis of Small and Mid-sized Players based in Rest of the World (Peer Group VIII)
9.4. Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Chapter Overview
10.2. Partnership Models
10.3. Cell and Gene Therapy Contract Research Organizations: Partnerships and Collaborations
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.3. Analysis by Year and Type of Partnership
10.3.4. Analysis by Area of Expertise
10.3.5. Most Active Players: Analysis by Number of Partnerships
10.3.6. Analysis by Geography
10.3.6.1. Intracontinental and Intercontinental Agreements
10.3.6.2. Local and International Agreements

11. MERGERS AND ACQUISITIONS

11.1. Chapter Overview
11.2. Merger and Acquisition Models
11.3. Cell and Gene Therapy CROs: Mergers and Acquisitions
11.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
11.3.2. Analysis by Type of Agreement
11.3.3. Analysis by Key Value Drivers
11.3.4. Analysis by Year of Agreement and Key Value Drivers
11.3.5. Most Active Acquirers: Analysis by Number of Acquisitions
11.3.6. Analysis by Geography
11.3.6.1. Local and International Mergers and Acquisitions
11.3.6.2. Intracontinental and Intercontinental Mergers and Acquisitions
11.3.7. Key Acquisitions: Deal Multiples

12. KEY ACQUISITION TARGETS

12.1. Chapter Overview
12.2. Key Assumptions and Parameters
12.3. Scope and Methodology
12.4. Potential Strategic Acquisition Targets Amongst Small Players
12.5. Potential Strategic Acquisition Targets Amongst Mid-sized Players

13. CLINICAL TRIAL ANALYSIS

13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Cell Therapy: Clinical Trial Analysis
13.3.1. Analysis by Trial Registration Year
13.3.2. Analysis by Trial Status
13.3.3. Analysis by Trial Registration Year and Trial Status
13.3.4. Analysis by Trial Phase
13.3.5. Analysis by Trial Registration Year and Trial Phase
13.3.6. Analysis of Enrolled Patient Population by Trial Registration Year
13.3.7. Analysis of Enrolled Patient Population by Trial Status
13.3.8. Analysis of Enrolled Patient Population by Trial Phase
13.3.9. Analysis by Therapeutic Area
13.3.10. Analysis by Study Design
13.3.11. Analysis by Type of Sponsor / Collaborator
13.3.12. Most Active Industry Players: Analysis by Number of Registered Trials
13.3.13. Analysis of Number of Registered Trials by Geography
13.3.14. Analysis of Number of Registered Trials by Trial Status and Geography
13.3.15. Analysis of Enrolled Patient Population by Geography
13.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography
13.4. Gene Therapy: Clinical Trial Analysis
13.4.1. Analysis by Trial Registration Year
13.4.2. Analysis by Trial Status
13.4.3. Analysis by Trial Registration Year and Trial Status
13.4.4. Analysis by Trial Phase
13.4.5. Analysis by Trial Registration Year and Trial Phase
13.4.6. Analysis of Enrolled Patient Population by Trial Registration Year
13.4.7. Analysis of Enrolled Patient Population by Trial Status
13.4.8. Analysis of Enrolled Patient Population by Trial Phase
13.4.9. Analysis by Therapeutic Area
13.4.10. Analysis by Study Design
13.4.11. Analysis by Type of Sponsor / Collaborator
13.4.12. Most Active Industry Players: Analysis by Number of Registered Trials
13.4.13. Analysis of Number of Registered Trials by Geography
13.4.14. Analysis of Number of Registered Trials by Trial Status and Geography
13.4.15. Analysis of Enrolled Patient Population by Geography
13.4.16. Analysis of Enrolled Patient Population by Trial Status and Geography

14. TOTAL COST OF OWNERSHIP

14.1 Chapter Overview
14.2. Assumptions and Methodology
14.3. Key Parameters
14.4 Total Cost of Ownership (Sample Dataset)
14.4.1 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20
14.4.2. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by CAPEX, Y0
14.4.3. Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations: Analysis by OPEX, Y1-Y20

15. SWOT ANALYSIS

15.1. Chapter Overview
15.2. Strengths
15.3. Weaknesses
15.4. Opportunities
15.5. Threats
15.6. Concluding Remarks

16. GLOBAL CELL AND GENE THERAPY CRO MARKET

16.1. Chapter Overview
16.2. Key Assumptions and Methodology
16.3. Global Cell and Gene Therapy CRO Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
16.3.1. Scenario Analysis
16.3.1.1. Conservative Scenario
16.3.2.2. Optimistic Scenario
16.4. Key Market Segmentations

17. CELL AND GENE THERAPY CRO MARKET, BY TYPE OF CELL THERAPY

17.1. Chapter Overview
17.2. Key Assumptions and Methodology
17.3. Cell and Gene Therapy CRO Market: Distribution by Type of Cell Therapy
17.3.1. CAR-T: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
17.3.2. TCR-T: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
17.3.2. CAR-NK: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
17.3.3. Others: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
17.4. Data Triangulation and Validation

18. CELL AND GENE THERAPY CRO MARKET, BY TYPE OF GENETIC MODIFICATION

18.1. Chapter Overview
18.2. Key Assumptions and Methodology
18.3. Cell and Gene Therapy CRO Market: Distribution by Type of Genetic Modification, 2018, 2024 and 2035
18.3.1. Ex vivo: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
18.3.2. In vivo: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
18.4. Data Triangulation and Validation

19. CELL AND GENE THERAPY CRO MARKET, BY STAGE OF DEVELOPMENT

19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Cell and Gene Therapy CRO Market: Distribution by Stage of Development
19.3.1. Clinical: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.3.2. Preclinical: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.3.3. Discovery: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
19.4. Data Triangulation and Validation

20. CELL AND GENE THERAPY CRO MARKET, BY THERAPEUTIC AREA

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Cell and Gene Therapy CRO Market: Distribution by Therapeutic Area
20.3.1. Oncological Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.2. Rare Diseases: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.3. Neurological Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.4. Metabolic Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.5. Musculoskeletal Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.6. Cardiovascular Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.7. Immunological Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.8. Dermatological Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.9. Infectious Diseases: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.10. Blood Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.3.11. Other Disorders: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
20.4. Data Triangulation and Validation

21. CELL AND GENE THERAPY CRO MARKET, BY END-USERS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Cell and Gene Therapy CRO Market: Distribution by End-users
21.3.1. Industry Players: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.3.2. Non-Industry Players: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation

22. CELL AND GENE THERAPY CRO MARKET, BY KEY GEOGRAPHICAL REGIONS

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Cell and Gene Therapy CRO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
22.3.1. North America: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.1.1. US: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.1.2. Canada: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.1.3. Rest of North America: Historical Trends (since 2018) and Forecasted Estimates (till
2035)
22.3.2. Europe: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.1. Spain: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.2. France: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.3. UK: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.4. Italy: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.5. Germany: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.6. Russia: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.2.7. Rest of Europe: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3. Asia-Pacific: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3.1. China: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3.2. Japan: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3.3. South Korea: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3.4. India: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3.5. Australia: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.3.3.6. Rest of Asia-Pacific: Historical Trends (since 2018) and Forecasted Estimates (till
2035)
22.3.4. Rest of the World: Historical Trends (since 2018) and Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation and Validation

23. EXECUTIVE INSIGHTS

23.1. Chapter Overview
23.2. Company A
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Business Development Executive
23.3. Company B
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Clinical Trial Manager
23.4. Company C
23.4.1. Company Snapshot
23.4.2. Interview Transcript: Former Director, Marketing and Sales
23.5. Company D
23.5.1. Company Snapshot
23.5.2. Interview Transcript: Former President

24. CONCLUDING REMARKS25. APPENDIX I: TABULATED DATA26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: CROs Market Landscape (I /II)
Figure 4.2 Executive Summary: CROs Market Landscape (II /II)
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Cell Therapy Clinical Trial Analysis
Figure 4.6 Executive Summary: Gene Therapy Clinical Trial Analysis
Figure 4.7 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Stages of the Drug Development Process
Figure 5.2 Type of Services Offered by CROs
Figure 5.3 Classification of ATMPs
Figure 5.4 Types of Cells Incorporated in Cell Therapy Medicinal Products
Figure 5.5 Advantages of Outsourcing Operations to CROs
Figure 5.6 Risks Associated with Outsourcing to CROs
Figure 6.1 Outsourcing Models
Figure 6.2 Key Characteristics of Transactional Outsourcing Model
Figure 6.3 Key Characteristics of Performance -based Business Model
Figure 6.4 Role of a CRO in Different Phases of Drug Development
Figure 6.5 Key Considerations for Outsourcing Cell and Gene Therapy Operations
Figure 7.1 Cell and Gene Therapy CROs: Distribution by Year of Establishment
Figure 7.2 Cell and Gene Therapy CROs: Distribution by Company Size
Figure 7.3 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Region)
Figure 7.4 Cell and Gene Therapy CROs: Distribution by Location of Headquarters (Country)
Figure 7.5 Cell and Gene Therapy CROs: Distribution by Area of Expertise
Figure 7.6 Cell and Gene Therapy CROs: Distribution by Type of Cell Therapy
Figure 7.7 Cell and Gene Therapy CROs: Distribution by Scale of Operation
Figure 7.8 Cell and Gene Therapy CROs: Distribution by Type of Preclinical Services Offered
Figure 7.9 Cell and Gene Therapy CROs: Distribution by Type of Clinical Services Offered
Figure 7.10 Cell and Gene Therapy CROs: Distribution by Type of Regulatory Services Offered
Figure 7.11 Cell and Gene Therapy CROs: Distribution by Type of General Services Offered
Figure 8.1 CMIC: Annual Revenues, FY 2018 Onwards (JPY Billion)
Figure 8.2 Labcorp: Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 8.3 Linical: Annual Revenues, FY 2021 Onwards (JPY Million)
Figure 8.4 Medpace: Annual Revenues, FY 2018 Onwards (USD Million)
Figure 8.5 Syneos Health: Annual Revenues, FY 2018 Onwards (USD Billion)
Figure 9.1 Benchmark Analysis: Distribution of Players by Location of Headquarters and Company Size
Figure 9.2 Benchmarking Analysis: Small Players Based in North America (Peer Group I)
Figure 9.3 Benchmarking Analysis: Mid-Sized Players Based in North America (Peer Group II)
Figure 9.4 Benchmarking Analysis: Large and Very Large Players Based in North America (Peer Group III)
Figure 9.5 Benchmarking Analysis: Small Players Based in Europe (Peer Group IV)
Figure 9.6 Benchmarking Analysis: Mid-sized Players Based in Europe (Peer Group V)
Figure 9.7 Benchmarking Analysis: Large and Very Large Players Based in Europe (Peer Group VI)
Figure 9.8 Benchmarking Analysis: Small, Mid-sized, Large and Very Large Players Based in Asia-Pacific (Peer Group VII)
Figure 9.9 Benchmarking Analysis: Small and Mid-sized Players Based in Rest of the World (Peer Group VIII)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-wise Trend, since 2015
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Area of Expertise
Figure 10.5 Most Active Players: Distribution by Number of Partnerships
Figure 10.6 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 10.7 Partnerships and Collaborations: Local and International Agreements
Figure 11.1 Mergers and Acquisitions: Cumulative Year-wise Trend, since 2015
Figure 11.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 11.3 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 11.4 Mergers and Acquisitions: Distribution by Year of Agreement and Key Value Drivers
Figure 11.5 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 11.6 Local and International Mergers and Acquisitions
Figure 11.7 Intercontinental and Intracontinental Mergers and Acquisitions
Figure 11.8 Mergers and Acquisitions: Deal Multiples Based on Revenues
Figure 13.1 Clinical Trial Analysis for Cell Therapies: Scope and Methodology
Figure 13.2 Clinical Trial Analysis for Gene Therapies: Scope and Methodology
Figure 13.3 Clinical Trial Analysis for Cell Therapies: Cumulative Year-wise Trend, since 2018
Figure 13.4 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Status
Figure 13.5 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year and Trial Status, since 2018
Figure 13.6 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Phase
Figure 13.7 Clinical Trial Analysis for Cell Therapies: Distribution by Trial Registration Year and Trial Phase, since 2018
Figure 13.8 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Registration Year, since 2018
Figure 13.9 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.10 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.11 Clinical Trial Analysis for Cell Therapies: Distribution by Therapeutic Area
Figure 13.12 Clinical Trial Analysis for Cell Therapies: Distribution by Study Design
Figure 13.13 Clinical Trial Analysis for Cell Therapies: Distribution by Type of Sponsor / Collaborator
Figure 13.14 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 13.15 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Registered Trials by Geography
Figure 13.16 Clinical Trial Analysis for Cell Therapies: Distribution of Number of Registered Trials by Trial Status and Geography
Figure 13.17 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Geography
Figure 13.18 Clinical Trial Analysis for Cell Therapies: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 13.19 Clinical Trial Analysis for Gene Therapies: Cumulative Year-wise Trend, since 2018
Figure 13.20 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Status
Figure 13.21 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Trial Status, since 2018
Figure 13.22 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Phase
Figure 13.23 Clinical Trial Analysis for Gene Therapies: Distribution by Trial Registration Year and Trial Phase, since 2018
Figure 13.24 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Registration Year, since 2018
Figure 13.25 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status
Figure 13.26 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Phase
Figure 13.27 Clinical Trial Analysis for Gene Therapies: Distribution by Therapeutic Area
Figure 13.28 Clinical Trial Analysis for Gene Therapies: Distribution by Study Design
Figure 13.29 Clinical Trial Analysis for Gene Therapies: Distribution by Type of Sponsor / Collaborator
Figure 13.30 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 13.31 Clinical Trial Analysis for Gene Therapies: Distribution of Number of Registered Trials by Geography
Figure 13.32 Clinical Trial Analysis for Gene Therapies: Distribution of Number of Registered Trials by Trial Status and Geography
Figure 13.33 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Geography
Figure 13.34 Clinical Trial Analysis for Gene Therapies: Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 14.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 14.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 14.3 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0-Y20 (USD Million)
Figure 14.4 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y0: Distribution of CAPEX
Figure 14.5 Total Cost of Ownership for Large / Very Large Cell and Gene Therapy Contract Research Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 15.1 Cell and Gene Therapy Service Providers: SWOT Analysis
Figure 15.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 16.1 Global Cell and Gene Therapy CRO Market, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 16.2 Global Cell and Gene Therapy CRO Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 16.3 Global Cell and Gene Therapy CRO Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 17.1 Cell and Gene Therapy CRO Market: Distribution by Type of Cell Therapy, 2018 , 2024 and 2035
Figure 17.2 Cell and Gene Therapy CRO Market for CAR-T, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.3 Cell and Gene Therapy CRO Market for TCR-T, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.4 Cell and Gene Therapy CRO Market for CAR-NK, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 17.5 Cell and Gene Therapy CRO Market for Others, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.1 Cell and Gene Therapy CRO Market: Distribution by Type of Genetic Modification, 2018, 2024 and 2035
Figure 18.2 Cell and Gene Therapy CRO Market for Ex vivo, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 18.3 Cell and Gene Therapy CRO Market for In vivo, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.1 Cell and Gene Therapy CRO Market: Distribution by Stage of Development, 2018, 2024 and 2035
Figure 19.2 Cell and Gene Therapy CRO Market for Clinical, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.3 Cell and Gene Therapy CRO Market for Preclinical, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 19.4 Cell and Gene Therapy CRO Market for Discovery, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.1 Cell and Gene Therapy CRO Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
Figure 20.2 Cell and Gene Therapy CRO Market for Oncological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.3 Cell and Gene Therapy CRO Market for Rare Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.4 Cell and Gene Therapy CRO Market for Neurological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.5 Cell and Gene Therapy CRO Market for Metabolic Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.6 Cell and Gene Therapy CRO Market for Musculoskeletal Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.7 Cell and Gene Therapy CRO Market for Cardiovascular Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.8 Cell and Gene Therapy CRO Market for Immunological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.9 Cell and Gene Therapy CRO Market for Dermatological Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.10 Cell and Gene Therapy CRO Market for Infectious Diseases, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 20.11 Cell and Gene Therapy CRO Market for Blood Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 20.12 Cell and Gene Therapy CRO Market for Other Disorders, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.1 Cell and Gene Therapy CRO Market: Distribution by End-users, 2018, 2024 and 2035
Figure 21.2 Cell and Gene Therapy CRO Market for Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Cell and Gene Therapy CRO Market for Non-Industry Players, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 22.1 Cell and Gene Therapy CRO Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 22.2 Cell and Gene Therapy CRO Market in North America, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Cell and Gene Therapy CRO Market in the US, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.4 Cell and Gene Therapy CRO Market in Canada, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.5 Cell and Gene Therapy CRO Market in Rest of North America, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 22.6 Cell and Gene Therapy CRO Market in Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.7 Cell and Gene Therapy CRO Market in Spain, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.8 Cell and Gene Therapy CRO Market in France, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.9 Cell and Gene Therapy CRO Market in the UK, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.10 Cell and Gene Therapy CRO Market in Italy, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.11 Cell and Gene Therapy CRO Market in Germany, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.12 Cell and Gene Therapy CRO Market in Russia, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.13 Cell and Gene Therapy CRO Market in Rest of Europe, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.14 Cell and Gene Therapy CRO Market in Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.15 Cell and Gene Therapy CRO Market in China, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.16 Cell and Gene Therapy CRO Market in Japan, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.17 Cell and Gene Therapy CRO Market in South Korea, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.18 Cell and Gene Therapy CRO Market in India, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.19 Cell and Gene Therapy CRO Market in Australia, Historical Trends (since 2018) and Forecasted Estimates (till 2035) (USD Million)
Figure 22.20 Cell and Gene Therapy CRO Market in Rest of Asia-Pacific, Historical Trends (since 2018) and Forecasted Estimates (till 2035)
(USD Million)
Figure 22.21 Cell and Gene Therapy CRO Market in Rest of the World, Historical Trends
(since 2018) and Forecasted Estimates (till 2035)
Figure 24.1 Concluding Remarks: Overall Market Landscape
Figure 24.2 Concluding Remarks: Partnerships and Collaborations
Figure 24.3 Concluding Remarks: Mergers and Acquisitions
Figure 24.4 Concluding Remarks: Clinical Trial Analysis for Cell Therapies
Figure 24.5 Concluding Remarks: Clinical Trial Analysis for Gene Therapies
Figure 24.6 Concluding Remarks: Market Sizing and Opportunity Analysis (I / II)
Figure 24.7 Concluding Remarks: Market Sizing and Opportunity Analysis (II / II)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

4Clinics
AbbVie
Absorption Systems (Acquired by Pharmaron)
Accelera
AccelLAB
Accellacare
Accelovance
Accelsiors
Advanced BioScience Laboratories
Advanced Cell Diagnostics
Aginko Research
Aixial
Allucent (Formally known as CATO SMS)
Altasciences
Cencora ( Formally known as AmerisourceBergen)
Amgen
Amulet Capital Partners
Ankarys Therapeutics
Applied StemCell
Ascension
Aurigon
Avance Biosciences
Avance Clinical
Avania
Binhui Bio
BioAccess
BioAgilytix
BioAnalytix
Bioheng
BioMarin Pharmaceutical
Biomedical Advanced Research and Development Authority
Biomere
BioRestorative Therapies
Bio-Techne
Biotect Services
BioVille
BrainStorm Cell Therapeutics
Cambridge Biomedical
Catalyst
Cato Research
Cellectar Biosciences
CellProtect Biotechnology
CellTrans
Charles River Laboratories
Chiltern
Chimeric Therapeutics
Citoxlab
City of Hope
Clean Cells
Clinical Network Services (CNS)
CMIC
CombiGene
Comparative Biosciences
Covance
CRC Oncology
Creative Biolabs
Crown Bioscience
Cryoport
CTI Clinical Trial & Consulting Services (CTI)
Datavant
Diamond Pharma Services (Acquired by ProPharma)
DiscGenics
EastHORN (Acquired by Novotech)
EMMES
Envigo
Ergomed
Evotec
Excelya
Fast-Track Drugs and Biologics
FGK Clinical Research
Forge Biologics
Frontage Laboratories
Geistak Pharmaceuticals
Genesis Biotechnology
GeneWerk
GenoSafe
Genprex
Genpro Research
Global Center for Medical Innovation
Gsap
HebeCell
Helixmith
HemaCare
HemoGenix
Hull Associates
ICON
ICRC-Weyer
Imanis Life Sciences
IMARC
Immunicum
IMS Health
INC Research (Acquired by Syneos Health)
Intertek Pharmaceutical Services
inVentiv Health
IPM Biotech
IQVIA
Ironstone Product Development
KCR
Kuopio Center for Gene and Cell Therapy (KCT)
Klinar CRO
Labcorp
Larix
LatinaBA
Linical Accelovance
Longmore 60 Biotech
Lovelace Biomedical
Lunaphore
MAXIS
MD Anderson Cancer Center
Medelis
Medidata
Medpace
MetabAxis
MI Bioresearch
MPI Research
NCGS
NeoGenomics
NetValue BioConsulting
Neurocore
NIH
Noble Life Sciences
Novartis Pharmaceuticals
NovaTrials
Novotech
Nuventra
OBiO Technology
OcellO B.V. (Acquired by Crown Bioscience)
OncoBay Clinical
Oncoshot
Parexel
Partex
PathoQuest
Pfizer
Pharmahungary
PharmaLex
Pharmaron
Pharmaseed
Pilgrim Quality Solutions
PPD
PRC Clinical
Precision for Medicine
Premier Research
Primera Analytical Solutions
Prolytix
ProPharma
ProtaGene (Formally known as Protagen Protein Services)
PSI CRO
PSN Research
QbD
QHP Capital
QPS
Q-Trials
Quality Assistance
Radyus Research
regenold
Renova Therapeutics
Research Dynamics
Rocket Pharmaceuticals
Strategic Preclinical Product Development (S2PD)
Sannova Analytical
Sanofi
Sarepta Therapeutics
SBH Sciences
Scandinavian CRO
SCiAN Services
Scope International
Sermes CRO
Sernova
Sinclair Research
SMS-oncology
SNBL USA
SUSMED
Svar Life Science
Syneos Health
Synteract (Acquired by Syneos Health)
TCTC Group
TechnoPharmaSphere
TFS Healthcare
TFS HealthScience
Theradex Oncology
TiGenix
Tofflon
Translational Drug Development (TD2)
Trialbee
Veeva Systems
Veristat
Vial
Vivotecnia
Vyriad
Wake Forest Innovations
WCCT Global
WCG IRB (Formerly known as WIRB)
Worldwide Clinical Trials
Xcell Bioscience

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a single user license, allowing one user access to the product.	€4253EUR$4,799USD£3,690GBP
SITE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6202EUR$6,999USD£5,382GBP
ENTERPRISE LICENSE PDF and Excel	The electronic report will be emailed to you. The file formats are PDF and Excel.	This is an enterprise license, allowing all employees within your organization access to the product.	€15950EUR$17,999USD£13,841GBP